| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K49290616 | CTRPv2 | pan-cancer | AAC | -0.038 | 0.6 |
| mRNA | narciclasine | CTRPv2 | pan-cancer | AAC | 0.017 | 0.6 |
| mRNA | AT-406 | CTRPv2 | pan-cancer | AAC | -0.025 | 0.6 |
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | -0.019 | 0.6 |
| mRNA | BRD9876:MK-1775 (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.055 | 0.6 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | -0.03 | 0.6 |
| mRNA | BRD-K34485477 | CTRPv2 | pan-cancer | AAC | -0.038 | 0.6 |
| mRNA | KX2-391 | CTRPv2 | pan-cancer | AAC | 0.016 | 0.6 |
| mRNA | GSK1059615 | CTRPv2 | pan-cancer | AAC | -0.023 | 0.6 |
| mRNA | CR-1-31B | CTRPv2 | pan-cancer | AAC | 0.016 | 0.6 |